Dr. Ai on Potential With Mogamulizumab in CTCL

Weiyun Z. Ai, MD, PhD
Published: Monday, Jan 22, 2018



Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, speaks to the relevance of mogamulizumab (Poteligeo) in treating Sezary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma (CTCL).

Data presented from the MAVORIC study revealed that mogamuliazumab is an active drug that clears the blood very quickly and is relatively well tolerated in treating patients with CTCL. The drug is especially active in Sezary syndrome, a leukemia form of CTCL in which statistics reflect an overall survival (OS) of 5 years. Though biologic therapy exists, a proportion of patients who progress require chemotherapy, and many of these patients acquire resistance to the chemotherapy.

With the FDA designation, mogamulizumab is now a novel treatment for patients who have progressed after receiving at least one systemic therapy.
 


Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, speaks to the relevance of mogamulizumab (Poteligeo) in treating Sezary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma (CTCL).

Data presented from the MAVORIC study revealed that mogamuliazumab is an active drug that clears the blood very quickly and is relatively well tolerated in treating patients with CTCL. The drug is especially active in Sezary syndrome, a leukemia form of CTCL in which statistics reflect an overall survival (OS) of 5 years. Though biologic therapy exists, a proportion of patients who progress require chemotherapy, and many of these patients acquire resistance to the chemotherapy.

With the FDA designation, mogamulizumab is now a novel treatment for patients who have progressed after receiving at least one systemic therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x